Machine Learning

Why a top security leader's move from a tech giant to a specialized firm signals a major shift in the fight for digital resilience. A deep dive.

Celldex is launching a pivotal Phase 3 trial for a drug that could be the first advanced therapy for two debilitating and untreated chronic hive conditions.

As AI systems grow more powerful, they also become vulnerable. A new German research initiative aims to build the tools to detect AI manipulation.

A mandatory disclosure from a Boston investment giant reveals its position in a $1.4B merger. What does it signal for the future of the auto industry?

Tempus AI's research at a key symposium shows its AI-driven edge, turning vast patient data into a powerful asset that could reshape oncology and investor outlooks.

Eli Lilly's groundbreaking leukemia drug data signals a major market shift, promising better patient outcomes and fortifying its long-term growth strategy.

Accenture is training 30,000 pros on Anthropic's Claude AI, tackling the biggest barrier to enterprise AI: moving from costly experiments to real value.

AskBio's gene therapies for Parkinson's and heart failure have received Japan's SAKIGAKE designation, promising a faster path to patients.

Aviz Networks just launched a certified SONiC distribution, aiming to break down the barriers of complexity and support that have kept open networking on the sidelines.

Target RWE's strategic hire of NoviSci co-founder Alan Brookhart signals a major push to master regulatory-grade real-world evidence. What does this mean?

With validated Phase 1b data, ONL Therapeutics' novel drug aims to protect vision cells, not just slow disease, in a challenge to current GA therapies.

Beyond the press release: How two strategic hires signal Plus Therapeutics' aggressive push to commercialize its CNSide platform and capture a $6B market.

A new lab system combines speed, multiplexing, and regulatory trust, promising to accelerate drug development and deepen our biological understanding.

A new alliance explores how inanimate microbes, or postbiotics, could become a novel weapon in oncology, starting with breast cancer research.

With stellar clinical data for its TERN-701 drug, Terns is raising massive capital to challenge Novartis and reshape the multi-billion-dollar CML market.

For those with severe PTSD and depression, hope is scarce. Biotech firm Compass Pathways is pioneering a psilocybin treatment that could change everything.

Independent 2025 endpoint security tests expose the top performers and true costs, offering CISOs a clear guide to navigating a complex market.

NUS scientists unveil a microneedle patch for plants, slashing waste and boosting growth. A new investment frontier in high-end, sustainable agriculture.

For patients with slow-growing lymphoma, "watch-and-wait" can be agonizing. A novel immunotherapy is showing promise in replacing anxiety with action.

Advanced chip packaging is the unsung hero of the AI revolution, with a market set to explode. But can the industry sustain its billion-dollar habit?